Shots:
- Teva & Sanofi have reported RELIEVE UCCD LTE study data evaluating duvakitug (450 or 900mg, SC, Q4W) in 130 pts with ulcerative colitis (UC) or Crohn’s disease (CD) following P-IIb (RELIEVE UCCD) induction study
- Trial showed that at Wk. 44 of maintenance, 58% (900mg) & 47% (450mg) of UC pts achieved clinical remission per mMS, while 55% & 41% of CD pts achieved endoscopic response per SES-CD, with consistent benefits across additional efficacy EPs in both indications
- This data reinforces results from the P-IIb (RELIEVE UCCD) induction study, where duvakitug demonstrated clinically meaningful responses vs PBO at wk. 14
Ref: Teva | Image: Teva & Sanofi | Press Release
Related News: Sanofi Reports P-III (LEAP2MONO) Trial Data on Venglustat in Type 3 Gaucher Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
